Genmab’s cash cow obtains new approval
![Foto: Stine Bidstrup](https://photos.watchmedier.dk/watchmedier/resize:fill:3840:0:0/plain/https://photos.watchmedier.dk/Images/article9383872.ece/ALTERNATES/schema-16_9/Jan%2520van%2520de%2520Winkel4.jpg)
Genmab’s money-spinning cancer drug Darzalex has received one more approval. This time, the FDA has approved the use of the drug in combination with pomalidomide, marketed as Pomalyst by US-based Celgene, and the steroid medication dexamethasone, for the treatment of patients with multiple myeloma.
Læs hele artiklen
Få adgang i 14 dage for 0 kr. Det kræver intet kreditkort, og du vil ikke overgå til et betalt abonnement efterfølgende.
Med din prøveperiode får du:
Få fuld adgang til dig og dine kollegaer
Start et gratis virksomhedsprøveabonnementRelaterede artikler
Genmab earns millions on new Darzalex approval
For abonnenter
Genmab’s Darzalex will not proceed to phase 2 in NHL
For abonnenter